| Lymphoglobuline (equine anti-thymocyte globulin) / Sanofi |
2005-000855-14: Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor. |
|
|
| Ongoing | 4 | 65 | Europe | NA, NA, RAPAMUNE*1MG 100 CPR, RAPAMUNE*2MG 30 CPR, RAPAMUNE*OS 60 ML 1 MG, THYMOGLOBULINE*IV 1F 25MG +F, RAPAMUNE*1MG 100 CPR, RAPAMUNE*2MG 30 CPR, RAPAMUNE*OS 60 ML 1 MG, THYMOGLOBULINE*IV 1F 25MG +F | AZIENDA OSPEDALIERA DI PADOVA | Acute rejection prophylaxis after single-double kidney transplantation from marginal donors making use of a not nephrotoxic immunosuppressive regimen. | | | | |
ChiCTR-OIN-17011174: A Study of Thymoglobuline? Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant |
|
|
| Recruiting | 4 | | | | The First Affiliated Hospital of Xi'an JiaoTong University; Sanofi (Beijing) Pharmaceutical Co., Ltd., Sanofi (Beijing) Pharmaceutical Co., Ltd. | Diseases of the kidney and urinary system | | | | |
NCT02745717: The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia |
|
|
| Completed | 4 | 60 | RoW | Thymoglobulin, Thymoglobuline, Cord blood, Cyclosporine Oral Product, cyclosporine A | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Tongji Hospital, Tongji University School of Medicine, Zhejiang Provincial Hospital of TCM | Severe Aplastic Anemia | 12/21 | 12/21 | | |
2011-002052-14: EURO-HIT-HLH European cooperative pilot study for testing Hybrid ImmunoTherapy for Hemophagocytic LymphoHistiocytosis Studio cooperativo pilota per la valutazione della terapia immunologica combinata della Linfoistiocitosi Emofagocitica Familiare |
|
|
| Ongoing | 3/4 | 24 | Europe | THYMOGLOBULINE*1F 25MG 10ML, DESAMETASONE FOSF*IM EV 3F 4MG, ETOPOSIDE TEVA*FL 10ML 20MG/ML, METHOTREXATE*INIET 1FL 500MG20, THYMOGLOBULINE*1F 25MG 10ML, DESAMETASONE FOSF*IM EV 3F 4MG, ETOPOSIDE TEVA*FL 10ML 20MG/ML, METHOTREXATE*INIET 1FL 500MG20 | AZIENDA OSPEDALIERA MEYER, AOU Meyer, AOUMeyer, Florence, HistiozytoseHilfe e.V., Universitätsklinikum Hamburg Eppendorf, St. Anna Kinderkrebsforschung e.V. | Familial hemophagoytic lymphohistiocytosis Linfoistiocitosi emofagocitica familiare. | | | | |
2021-003282-36: Studying Conditioning Regimen In Pediatric Transplantation – AML |
|
|
| Ongoing | 3 | 230 | Europe | Cyclophosphamide, Melphalan, Fludarabine, Clofarabine, Concentrate for dispersion for infusion, Powder for solution for infusion, Powder for dispersion for infusion, Busilvex, Grafalon, Thymoglobuline | Västra Götalands Regionen, Funding application submitted. | Acute myeloid leukemia (AML) in children, AML is a type of blood cancer, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
2006-004067-53: A multicenter randomized study on the use of rabbit anti-T-Lymphocite globulin ATG different doses to prevent GVHD in children receiving allogenic stem cell transplantation |
|
|
| Ongoing | 3 | 200 | Europe | THYMOGLOBULINE*1F 25MG+1F 5ML, THYMOGLOBULINE*1F 25MG+1F 5ML | OSPEDALE POLICLINICO S. MATTEO | ematological malignant neoplasm | | | | |
2006-004598-83: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis ( ‘ASTIS’-TRIAL: Autologous Stem Cell Transplantation International Scleroderma Trial) |
|
|
| Ongoing | 3 | 15 | Europe | Cyclophosphamide, Filgrastim, Thymoglobuline, Methylprednisolone, Mesna, rbATG, Cyclophosphamide, Neupogen, Thymoglobuline, Solu-Medrone, Mesna, Cyclophosphamide, Neupogen, Thymoglobuline, Solu-Medrone, Mesna | EBMT (European group for Blood and Marrow Transplantation) | Severe systemic sclerosis | | | | |
2017-002545-30: Controlled trial to assess low intensity autologous stem cell transplant in refractory Crohn's Disease |
|
|
| Ongoing | 3 | 99 | Europe | Cyclophosphamide, Filgrastim, Fludarabine, Thymoglobuline, Powder for solution for injection, Solution for injection, Concentrate for solution for injection/infusion, Powder for solution for infusion, Cyclophosphamide, Filgrastim, Fludarabine, Thymoglobuline | Barts Health NHS Trust | Refractory Crohn's Disease, Crohn's Disease that has not responded to previous treatment, Diseases [C] - Digestive System Diseases [C06] | | | | |
2019-003723-37: rATG versus rATG combined with IVIG induction immunosuppression in HLA incompatible transplantation Randomizovaná, otevřená studie fáze III.b prokazující non-inferioritu indukční imunosuprese pomocí rATG ve srovnání s kombinací rATG a IVIG u HLA inkompatibilních pacientů po transplantaci ledvin |
|
|
| Not yet recruiting | 3 | 138 | RoW | Thymoglobuline 5 mg/ml, prášek pro infuzní roztok, Privigen 100 mg/ml infuzní roztok, Powder for concentrate for solution for infusion, Solution for infusion, Thymoglobuline 5 mg/ml prášek pro infuzní roztok, Privigen 100 mg/ml infuzní roztok | Institut klinické a experimentální medicíny (IKEM), Institut klinické a experimentální medicíny (IKEM) | Trial participants will be end-stage renal disease (ESRD) patients listed for deceased donor / living donor kidney transplantation with anti HLA antibody screening performed within 12 months before transplantation and with last DSA 1 000 - 5 000, negative CDC prior to transplantation. Pacienti v terminálním stadiu selhání ledvin (ESRD), kteří podstoupili transplantaci ledviny od zemřelého či žijícího dárce, a kteří mají preformované anti-HLA protilátky zjištěné screeningovým vyšetřením v průběhu 12 měsíců před transplantací, poslední zjištěné hladiny DSA v rozmezí 1 000–5 000 MFI a negativní CDC crossmatch., Kidney transplantation Transplantace ledvin, Not possible to specify | | | | |
2008-004884-20: Protocole Clinique de Phase II multicentrique non randomisé évaluant l’efficacité, la tolérance et la toxicité d’un conditionnement à intensité réduite combinant Clofarabine (Evoltra) + Busulfan IV (Busilvex) + ATG (Thymoglobuline) (CBT) chez des patients nécessitant une allogreffe pour une MDS, LAM ou une LAL à haut risque |
|
|
| Ongoing | 2 | 30 | Europe | Concentrate for solution for infusion, Evoltra, BUSILVEX, Thymoglobuline | CHU de Nantes | LAL Leucémie Aiguë lymphoblastiqueLAM Leucémie Aiguë Myéloblastique MDS Syndrome MyéloDysplasique | | | | |
2010-023560-40: Blood stem cell transplantation for patients with relapsiong-remitting multiple sclerosis, in whom standard treatment has failed. Blodstamcellstransplantation för patienter med skovvis förlöpande MS (multipel sklerosis), där standardbehandling givit otillräcklig effekt. |
|
|
| Ongoing | 2 | 120 | Europe | , Powder for solution for injection, Powder for infusion*, Solution for injection, Powder and solvent for dispersion for injection, Tysabri, Sendoxan, Thymoglobuline, Neupogen, Solu-Medrol | Uppsala l�ns landsting | Relapsing-remitting multiple sclerosis | | | | |
2007-001413-42: Study of Fludarabine based conditioning for Allogeneic Stem cell Transplantation for Myelofibrosis |
|
|
| Ongoing | 2 | 20 | Europe | FLUDARA, ALKERAN*1FL 50MG/10ML+FL 10ML, THYMOGLOBULINE*1F 25MG+1F 5ML, FLUDARA, ALKERAN*1FL 50MG/10ML+FL 10ML, THYMOGLOBULINE*1F 25MG+1F 5ML | AZIENDA OSPEDALIERA \"OSPEDALI RIUNITI DI BERGAMO\" (A.O. DI RILIEVO NAZIONALE) | MYELOFIBROSIS | | | | |
2009-012673-35: Etude pharmacocinétique et pharmacodynamique comparant deux posologies différentes de la Thymoglobuline® en transplantation rénale. |
|
|
| Ongoing | 2 | 20 | Europe | THYMOGLOBULINE® 5 mg/ml, THYMOGLOBULINE® 5 mg/ml | CHRU de TOURS | Renal transplantation | | | | |
2014-004849-26: Parachute trial: research on individualized dosing regimen of Thymoglobuline Parachute onderzoek: wetenschappelijk onderzoek naar een geïndividualiseerde dosering van het medicijn Thymoglobuline |
|
|
| Ongoing | 2 | 53 | Europe | Thymoglobuline, Thymoglobuline, Thymoglobuline | UMC Utrecht, Sanofi-Aventis | Leukemia and immunedeficiency syndromes Leukemie en immuundeficientie syndromen | | | | |
| Active, not recruiting | 2 | 177 | Europe | BX2, Busulfan Intravenous 2 days at 3.2 mg/kg/d, BX3, Busulfan Intravenous 3 days, BX4-Suspended, Busulfan intravenous 4 days | Institut Paoli-Calmettes | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 07/26 | 07/26 | | |
2020-000419-56: A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti-thymocyte globulin) for the prevention of rejection in patients who have received a kidney transplant. |
|
|
| Not yet recruiting | 2 | 40 | Europe | siplizumab, TCD601, Concentrate for solution for infusion, Powder for solution for infusion, Thymoglobuline | ITB-MED AB, ITB-MED AB | renal transplantation, kidney transplantation, Body processes [G] - Immune system processes [G12] | | | | |
NCT05214066: Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT |
|
|
| Recruiting | 2 | 60 | RoW | Rabbit ATG, Thymoglobuline | Chinese PLA General Hospital | aGVHD, cGVHD | 08/22 | 08/22 | | |
2022-001257-22: Efficacy of Romiplostim in Treatment of Severe Aplastic Anemia in Non-Asian Adults Previously Untreated With or Refractory to Immunosuppressive Therapy |
|
|
| Not yet recruiting | 2 | 16 | Europe | Powder for solution for injection, Capsule, soft, Solution for infusion, Nplate, NEORAL 100 mg, capsule molle, ATGAM 50 mg/mL, solution à diluer pour perfusion, THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion | Amgen, Inc., Amgen Inc. | Aplastic anemia (AA), Aplastic anemia (AA) is a condition that occurs when your body stops producing enough new blood cells, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
ChiCTR-ROC-17011235: A Retrospective, Multi-center Study of Rabbit Anti-thymocyte Immunoglobulin (Thymoglobuline) Induction Therapy in Kidney Transplant Recipients Using Organs Donated After Cardiac Death in China |
|
|
| Completed | N/A | 1 | | Rabbit Anti-thymocyte Immunoglobulin (Thymoglobuline) Induction Therapy | The First Affiliated Hospital of Xi'an Jiaotong University; SANOFI (CHINA) INVESTMENT CO., LTD. SHANGHAI BRANCH, Sanofi (Beijing) Pharmaceutical Co., Ltd. | 肾脏及泌尿系统疾病 | | | | |
| Completed | N/A | 958 | RoW | Basiliximab Injection, Simulect, rabbit ATG, Thymoglobuline | Gang Chen, Zhejiang University, First Affiliated Hospital, Sun Yat-Sen University, The First Affiliated Hospital of Zhengzhou University, Changhai Hospital | Kidney Transplant Rejection, Pediatric Kidney Disease | 07/22 | 09/23 | | |
